Vanquish has partnered with Orlando Health to develop next-generation AI-driven to detect aggressive, hard-to-treat cancers with low survival rates at their earliest stages. By leveraging AI, Vanquish aims to identify subtle cancerous changes with high precision, enabling earlier intervention. Once detected, this technology facilitates the targeted delivery of Natural Killer (NK) cell-derived extracellular vesicles (EVs) to tumors before the cancer spreads, maximizing therapeutic impact while preserving healthy tissue. This innovative approach offers a personalized, minimally invasive, and highly effective strategy to improve patient outcomes.